Skip to content
SimSonGrowth Intelligence
All opportunitiesproduct

Sitagliptin

SimSon already publishes 159 observed catalogue products for Sitagliptin while an FDA nitrosamine acceptable-intake limit dated 14 September 2026 is already in force, with 6 organisations publicly associated with FDA filings for the molecule — a near-term SELL opportunity.Source

TIMING
A dated catalyst is forcing analytical work now — a novel approval, an NDSRI limit, a loss of exclusivity or a generic filing wave.
Here: A dated catalyst scores 99.3/100 while SimSon already holds observed coverage.
DEPTH
SimSon demonstrates substantial observed public catalogue depth for the molecule.
Here: SimSon publicly lists 159 products for this API family (threshold 20).
ACCESS
Public filings, trials or regulatory records expose identifiable organisations associated with the molecule. This is NOT a claim that any of them is a SimSon customer.
Here: 6 organisation(s) are publicly associated with filing activity for this molecule. This is not a customer claim.
Recommended action
sell

Take coverage SimSon already has to market.

84.2/ 100 opportunity score
Medium confidenceMedium because competitor scarcity could not be scored from public evidence.
Recommended move

Take SimSon's existing sitagliptin coverage to the 6 organisations publicly associated with it.

First step: Review the buyer candidates and mark which are already SimSon accounts — the system cannot tell.

Review buyer candidates
Urgency
Act now
The catalyst lands today, 2026-09-14.
Owner
Not set
Owner is not set: the system has no access to SimSon's org chart and will not guess one.
Value — not public
Cannot be established
Revenue and margin are not public. This ranks the strength of the public signal, not the size of the prize — see what internal data would settle it.

Why now

2 dated catalysts
  1. ndsri ai limitSource

    7-Nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3-a]pyrazine (NTTP)

    base 89.3 × 1 recency = 89.3 / 100

  2. patent expirySource

    Orange Book patent 12295953 expiry

    base 80 × 0.15 recency = 12 / 100

Why SimSon

Observed from SimSon public catalogue · 14 SEPT 2026
159publicly observed catalogue products for sitagliptin

Observed from SimSon’s own public catalogue pages. This measures published coverage, not inventory, and it is not a statement that SimSon can synthesise any specific compound.

SimSon demonstrates adjacent public catalogue coverage: 159 products observed on its own sitagliptin API page, including 5 nitroso products and 3 isotope-labelled products. This is capability evidence; it is not a statement that SimSon can synthesise any specific compound.Source

Total products
159
Nitrosamine-related
5
Isotope-labelled
3
Publicly claimed classes touched

nitrosamine · isotope labelled · impurity standards

Organisations publicly associated with this molecule

6 public filing associations

Each organisation below is publicly associated with development or filing activity for this molecule through its own FDA application. They are buyer-candidates. The system has no way to know whether any is already a SimSon customer, and does not claim one.

Scroll sideways for the full table

OrganisationFDA relationshipApplicationStatusDateEvidence
APOTEXGeneric applicantANDA202425approval20 JAN 2026View
APOTEXGeneric applicantANDA202426approval30 APR 2026View
PH HEALTHGeneric applicantANDA204144approval04 JUN 2025View
SANDOZGeneric applicantANDA202387approval14 JAN 2026View
SANDOZGeneric applicantANDA202388approval02 DEC 2025View
WATSON LABS INCGeneric applicantANDA202327approval29 DEC 2025View

How this decision was reached

sell
Rule fired
R2_DEPTH_TIMING

SimSon already publishes a material catalogue position for this molecule and a dated catalyst is in force. The standards exist; the demand event has happened.

SimSon already holds 159 observed products and a dated catalyst scores 99.3/100.

This is a system recommendation, not system evidence. It was selected by a fixed rule evaluated top to bottom over the values above — no model, no judgement. Change the inputs and the rule changes with them.

SELL — rule R2_DEPTH_TIMING. SimSon already holds 159 observed products and a dated catalyst scores 99.3/100.

Opportunity score

Weighted over 80 of 100 available points · audit-01-phase2-v1
Market activity
62.1
Regulatory catalyst
99.3
Competitor scarcity
Not scored
Capability adjacency
100.0
Evidence quality
70.0
Why competitor scarcity is not scored

Identity-grade competitor coverage was insufficient across the three suppliers this dimension requires. The 20 weight points it would have carried were removed from the denominator rather than scored as zero, so the remaining dimensions keep their relative influence.

  • Daicel Chiral Technologies India Pvt. Ltd.NOT CHECKED — supplier catalogue did not expose sufficient identity data

    No permitted candidate page exposed enough identity data to resolve this molecule at identity grade.

  • Veeprho Laboratories Pvt. Ltd.NOT CHECKED — supplier catalogue did not expose sufficient identity data

    No permitted candidate page exposed enough identity data to resolve this molecule at identity grade.

A false competitive gap is materially worse than a missing scarcity score, so the dimension stays unscored until the evidence standard is met.

Market activity components
Distinct ANDA sponsors
4
Marketed products
35
Distinct trial sponsors
Not checked

ClinicalTrials.gov disallows our agent on /api/ in its robots.txt. The trial component was omitted from the weighted average rather than scored zero, and no substitute source was used.

Evidence ledger

9 items · 9 primary
  1. Retrieval datePrimaryLive retrieval
    SimSon Pharma LimitedSimSon public catalogueobserved

    SimSon catalogue coverage — sitagliptin

    159 products observed on https://www.simsonpharma.com/products/Sitagliptin

    https://www.simsonpharma.com/products/Sitagliptin

    Retrieved 14 SEPT 2026

  2. Retrieval datePrimaryLive retrieval
    U.S. Food and Drug AdministrationopenFDA Drugs@FDAobserved

    ANDA202327 — WATSON LABS INC

    ANDA202327; sponsor WATSON LABS INC

    https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name%3A%22sitagliptin%22&limit=100

    Retrieved 14 SEPT 2026

  3. Retrieval datePrimaryLive retrieval
    U.S. Food and Drug AdministrationopenFDA Drugs@FDAobserved

    ANDA202425 — APOTEX

    ANDA202425; sponsor APOTEX

    https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name%3A%22sitagliptin%22&limit=100

    Retrieved 14 SEPT 2026

  4. Retrieval datePrimaryLive retrieval
    U.S. Food and Drug AdministrationopenFDA Drugs@FDAobserved

    ANDA202426 — APOTEX

    ANDA202426; sponsor APOTEX

    https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name%3A%22sitagliptin%22&limit=100

    Retrieved 14 SEPT 2026

  5. Retrieval datePrimaryLive retrieval
    U.S. Food and Drug AdministrationopenFDA Drugs@FDAobserved

    ANDA204144 — PH HEALTH

    ANDA204144; sponsor PH HEALTH

    https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name%3A%22sitagliptin%22&limit=100

    Retrieved 14 SEPT 2026

  6. Retrieval datePrimaryLive retrieval
    U.S. Food and Drug AdministrationopenFDA Drugs@FDAobserved

    ANDA202387 — SANDOZ

    ANDA202387; sponsor SANDOZ

    https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name%3A%22sitagliptin%22&limit=100

    Retrieved 14 SEPT 2026

  7. Retrieval datePrimaryLive retrieval
    U.S. Food and Drug AdministrationopenFDA Drugs@FDAobserved

    ANDA202388 — SANDOZ

    ANDA202388; sponsor SANDOZ

    https://api.fda.gov/drug/drugsfda.json?search=openfda.substance_name%3A%22sitagliptin%22&limit=100

    Retrieved 14 SEPT 2026

  8. Retrieval datePrimaryLive retrieval
    U.S. Food and Drug AdministrationFDA CDER CPCA NDSRI acceptable-intake limitsobserved

    7-Nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3-a]pyrazine (NTTP) — Sitagliptin

    7-Nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3-a]pyrazine (NTTP); parent API Sitagliptin; potency category 2; 100 ng/day

    https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits

    Retrieved 14 SEPT 2026

  9. Retrieval datePrimaryLive retrieval
    U.S. Food and Drug AdministrationFDA Orange Book data filesobserved

    Orange Book patent row

    N 219122 product 001

    https://www.fda.gov/media/76860/download?attachment

    Retrieved 13 SEPT 2026

What internal SimSon data would change this decision?

Everything above was built from information anyone can retrieve. The scoring is deterministic and the evidence is cited — but each of the following would sharpen this recommendation materially, and none of it is public.

Realised selling price and margin per catalogue item

Every opportunity here is ranked by signal strength, never by profit. A high-scoring molecule may be one SimSon sells at its thinnest margin.

Would be resolved by: SimSon price book and cost model

Historical RFQs and enquiry conversion

The best predictor of the next order is usually the last unconverted enquiry. None of that is public.

Would be resolved by: SimSon CRM and enquiry log

Existing customer relationships

The organisations listed as buyer-candidates may already be SimSon customers. The system has no way to tell, which is exactly why it never calls them leads.

Would be resolved by: SimSon customer master

Inventory and lead time

A listed product is not an in-stock product. A SELL recommendation assumes availability the catalogue does not state.

Would be resolved by: SimSon ERP

Actual competitor pricing, stock and terms

Public catalogues show listings, never terms. Even where a competitor listing is observed, it says nothing about price or availability.

Would be resolved by: Not public — sales intelligence or direct enquiry

Limitations recorded for this opportunity

competitor scarcity is NOT SCORED (0 of the 3 required suppliers hold an identity-grade verdict); the ClinicalTrials.gov trial-sponsor component is omitted from market activity because that publisher's robots.txt disallows our agent on /api/ — omitted, not scored zero; catalogue depth is capability evidence only and carries no demand claim.Source

Computed 14 SEPT 2026Weights audit-01-phase2-v1Run phase2-current-evidence-v1